Characteristics of serum protein binding of felodipine

Research Communications in Molecular Pathology and Pharmacology

Volumn 94, Issue 1, 1996, Pages 73-88

  Valle, M ^a   Esteban, M ^a   Rodriguez Sasiain J M ^a   Calvo, R ^a   Aguirre, C ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FELODIPINE; OROSOMUCOID;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CANCER; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; LIVER DISEASE; MALE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; ULTRAFILTRATION;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PROTEINS; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FELODIPINE; FEMALE; HUMANS; KIDNEY DISEASES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEOPLASMS; OROSOMUCOID; PROTEIN BINDING; SERUM ALBUMIN;

EID: 0029963465     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Aguirre, C., Rodríguez-Sasiaín, J.M., Calvo, R. (1994). Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents. Cancer. Chemotherap. Pharmacol. 34, 86-88.
2. Blain, P.G., Mucklow, J.C., Rawlins, M.D., Roberts, D.F., Routledge, P.A., Shand, D.G. (1986). Determinants of plasma a1-acid glycoprotein concentration in health. Br. J. Clin. Pharmacol. 12, 500-502.
3. Blychert, E., Edgar, B., Elmfeldt, D., Hedner, T. (1991). A population study of the pharmacokinetics study. Br. J. Clin. Pharmacol. 31, 15-24.
4. Calvo, R., Carlos, R., Erill, S. (1982). Effects of carbamylation of plasma proteins and competitive displacers on drug binding in uremia. Pharmacology. 24, 248-252.
5. Costela, J.L., Jiménez, R., Calvo, R., Suárez, E., Carlos, R. (1996). Serum protein binding in patients with renal failure or hepatic cirrhosis. Acta Anestesiol Scand. 40(6), 741-745.
6. Dunselman, P.H.J.M., Edgar, B. (1991). Felodipine clinical pharmacokinetics. Clin. Pharmacokinet. 21, 418-430.
7. Edgar, B., Regårdh, C.G., Johnsson, G. (1985). Felodipine kinetics in healthy men. Clin. Pharmacol. Ther. 38, 205-211.
8. Edgar, B., Regårdh, C.G., Attman, P.D., Aurell, M., Herlitz, H., Johnsson, G. (1989). Pharmacokinetics of felodipine in patients with impaired renal function. Br. J. Clin. Pharmacol. 27, 67-74.
9. Fukui, T., Hameroff, S.R., Gandolfi, J. (1984). Alpha-1-acid glycoprotein and beta-endorphin alterations in chronic pain patients. Anesthesiology. 60, 494-496.
10. Furberg, C.D., Pstay, B.M., Meyer, S.V. (1995). Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 92, 1326-1331.
11. Horton, R. (1995). Spinning the risks and benefits of calcium antagonists. Lancet. 346, 586-587.
12. Hunninghake, D., Crisolia, S. (1966). A sensitive and convenient micromethod for estimation of urea, citrulline and carbamyl derivatives. Anal. Biochem. 16, 200-205.
13. Kleinbloesem, C.H., Van Brummelen, P., Van Harten, J., Danhof, M., Breimer, D.D. (1985). Nifedipine: Influence of renal function on pharmacokinetic/hemodynamic relationship. Clin. Pharmacol. Ther. 37, 563-574.
14. Larsson, R. Kalberg, B.E., Gelin, A., Åberg, J., Regårdh, C.G. (1990). Acute and steady-state pharmacokinetics and antihipertensive effects of felodipine in patients with normal and impaired renal functions. J. Clin. Pharmacol. 30, 1020-1030.
15. Ljung, B. (1985). Vascular selectivity of felodipine. Drugs. 29 (Suppl. 2), 46-58.
16. Otto, J., Lasko, L.J. (1986). Protein binding of nifedipine. J. Pharm. Pharmacol. 38, 399-400.
17. Pinquier JL, Urien S., Chaumet-riffaud P., Tillement J.P. (1989). Differences in the serum binding determinants of isradipine and darodipine-consequences for serum protein binding in various diseases. Br. J. Clin. Pharmacol. 28, 587-592.
18. Piafsky, K.M. (1980). Disease-induced changes in the plasma binding of basic drugs. Clin. Pharmacokinet. 5, 246-262.
19. Routledge, P.A. (1986a). Respective parts of the different plasma proteins and blood cells in the overall binding of drugs. In protein binding and drug transport, eds Tillement, JP. & Lindelaud, E; pp: 179-196. Stuttgart, New York: Schattauer.
20. Routledge, P.A. (1986b). The plasma protein binding of basic drugs. Br. J. Clin. Pharmacol. 22, 499-506.
21. Rudman, D., Treadwell, P.E., Vogler, W.R., Howard, C.H., Hollins, B. (1972). An abnormal orosomucoid in the plasma of patients with neoplasic disease. Cancer. Res. 32, 1951-1959.
22. Ruiz-Cabello, F., Erill, S. (1984). Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin. Pharmacol. Ther. 35, 691-695.
23. Tillement, J.P., Lhoste, F. & Giudicelli, J.F. (1978). Disease and drug protein binding. Clin. Pharmacokinet. 3, 144-154.
24. Verbeeck, R.K., Cardinal, J-A., Wallace, S.M. (1984). Effect of age and sex on the plasma binding of acidic and basic drugs. Eur. J. Clin. Pharmacol. 27, 91-97.
25. Wade, J.R., Sambol, N.C. (1995). Felodipine population dose-response and concentration-response relationship in patients with essential hypertension. Clin. Pharmacol. Ther. 57, 569-581.
26. Zini, R., Riant, P., Barré, J., Tillement, J.P. (1990). Disease-induced variations in plasma protein levels implications for drug dosage regimens (part I). Clin. Pharmacokinet. 19(2), 147-159.